Tengion (TNGNQ) Stock Price, News & Analysis

Company Overview

Tengion, Inc. is a clinical-stage regenerative medicine company focused on developing and commercializing novel therapeutics for the reconstruction and restoration of urinary, renal and vascular tissues. The company’s approach leverages proprietary tissue engineering technologies, including patient-derived cell therapy and biodegradable scaffolds, to create living implants that integrate into a patient’s body. Tengion’s research and development efforts aim to address organ failure and chronic disease through regenerative solutions that can reduce or eliminate the need for donor organs and long-term immunosuppression.

Key elements of Tengion’s development pipeline have included engineered tissue implants such as the Neo-Urinary Conduit, Neo-Kidney Augment and vascular graft constructs, all designed to restore function to damaged or diseased tissues. The company has pursued Phase I and II clinical studies of its lead candidates, working in collaboration with academic medical centers and surgical specialists to evaluate safety, feasibility and early efficacy endpoints. Tengion’s technology platform also supports the generation of customizable tissue matrices for a range of reconstructive applications.

Founded in 1989 and headquartered in Winston-Salem, North Carolina, Tengion has operated primarily within the United States, engaging in partnerships with regulatory agencies and contract development organizations to advance its clinical programs. Over its history, the company has navigated transitions from discovery and preclinical research to human trials, positioning itself within the broader regenerative medicine sector. Tengion’s leadership team comprises professionals with experience in biotechnology development, clinical operations and surgical innovation, all aimed at translating laboratory breakthroughs into therapeutic options for patients with unmet medical needs.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 1,060 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 8/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:TNGNQ
• CIK: N/A
• Web: www.tengion.com
• Phone: (336) 722-5855
• Fax: N/A
• Employees: 25
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -29.34